Macrolide Antibiotics Inhibit Aberrant Splicing in Myotonic Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for myotonic dystrophy are ineffective in addressing the underlying aberrant splicing caused by expanded repeats in the DMPK gene, leading to persistent symptoms with limited safety for long-term administration.
Innovation Solution
The use of erythromycin, clarithromycin, or azithromycin, or their pharmaceutically acceptable salts or ester forms, to inhibit aberrant splicing in genes associated with myotonic dystrophy, thereby improving symptoms such as muscle contraction and muscle weakness, and ensuring safety for long-term use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If symptomatic therapies such as diet therapy are given to patients, then patient comfort is improved for specific symptoms, but the underlying aberrant splicing is not addressed and disease progression continues
Solution Approach 1:
The patent uses splicing regulators as intermediary molecules that bind to the expanded CTG repeat transcripts to displace aberrant splicing regulators. This mediator approach allows the compound to indirectly correct the splicing defect without directly modifying the genetic mutation, thereby addressing the root cause while being compatible with existing symptomatic therapies
2Reliability
If aberrant splicing is inhibited to increase normally spliced product, then disease mechanism is addressed and symptom improvement is achieved, but safety for long-term administration must be ensured
Solution Approach 1:
The patent employs small molecule splicing regulators that can be administered transiently to achieve therapeutic effect. These short-acting compounds allow for flexible dosing and can be discontinued if adverse effects occur, providing a safety mechanism for long-term treatment while maintaining therapeutic effectiveness
Solution Approach 2:
The patent optimizes the chemical structure and binding affinity parameters of splicing regulator compounds to achieve selective binding to expanded repeat transcripts. By carefully tuning these parameters, the compounds achieve sufficient efficacy to correct splicing while minimizing off-target effects that could compromise long-term safety
Data Source
Figure 1
Figure 2(A)~2(B)
Figure 3
AI summary
The present invention provides a therapeutic agent for myotonic dystrophy which inhibits aberrant splicing responsible for myotonic dystrophy, resulting in an increase in a normally spliced product and thus improvement in a symptom of myotonic dystrophy, and is highly safe for use in long-term administration. The therapeutic agent for myotonic dystrophy comprises, as an active ingredient, at least one compound selected from the group consisting of erythromycin, clarithromycin and azithromycin, a pharmaceutically acceptable salt or hydrate thereof, or a prodrug thereof.